{
  "docId": "019de075-37cf-77a8-ac06-803553b19741",
  "docSlug": "fb1f3d8675ea71173cb7fbde0c578736",
  "documentTitle": "Sarissa Capital | Activist Presentation Deck | 36 slides",
  "authorId": "sarissa-capital",
  "authorName": "Sarissa Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 36,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a specific case study to undermine the credibility of a board nominee.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-37cf-77a8-ac06-803553b19741/19",
  "deckHref": "/decks/019de075-37cf-77a8-ac06-803553b19741",
  "deckJsonHref": "/decks/019de075-37cf-77a8-ac06-803553b19741.json",
  "deckAnchorHref": "/decks/019de075-37cf-77a8-ac06-803553b19741#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.16,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "callout",
      "text": "A simple search showed that Nancy Wysenski was charged with securities fraud and insider trading while she was Chief Commercial Officer and Executive Vice President at Vertex Pharmaceuticals (Dec 2009 - June 2012)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6991cf12-f581-4a5b-9d77-c07f0900cd34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "list",
      "text": "May 7, 2012, Vertex issued a press release announcing interim clinical trial results that were exaggerated. Wysenski on a conference call that day “noted that the number of patients who stood to benefit from the combination treatment under review exceeded 70,000--a market that could translate into billions of dollars in potential sales.” Vertex’s stock price rose quickly, from $37.41 a share the day before the announcement, to $58.12 the day of, and mere weeks later was trading at $64.85. Prior to the correction of the data, issued on May 29, 2012, Nancy Wysenski sold ~$22 M worth of stock",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37cfb2b2-281e-45e4-8751-b05b69a7f961",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "For example, Alkermes lead independent director Nancy Wysenski was accused in a securities fraud and insider trading suit of overstating clinical trial results and then profiting by selling ~$22M worth of stock",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94725ff0-1cea-4f7a-885b-2a2aa35f47eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Bloomberg Law",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c15d78b-fb54-4811-9045-2f7c8d087927",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "b8dea2a4-3656-45a3-8438-70f202a5a844",
      "evidence": "The slide explicitly details legal allegations and financial misconduct to discredit a nominee.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "7b33bdd2-a210-442a-b859-65ebe5034da0",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "Slides 13-20 present the struggles faced by Alkermes and its shareholders",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}